Kornimate/medical-research-clean huggingface dataset:
application of ultrasound artificial intelligence and elastography in differential diagnosis of breast nodules

Conditions: Breast Cancer

Summary: the application of computer-aided diagnosis (cad) technology "s-detect" enables qualitative and quantitative automated analysis of ultrasound images to obtain objective, repeatable and more accurate diagnostic results. the elastic contrast index (eci) technique, unlike conventional strain-elastic imaging techniques, can evaluate the elastic distribution in the region of interest. the purpose of the study was to evaluate the differential diagnosis value of ultrasound s-detect technology for benign and malignant breast nodules and evaluate the differential diagnosis consistency of the ultrasound s-detect technique and the examiner for benign and malignant breast nodules and explore the differential diagnosis value of samsung ultrasound elastic contrast index (eci) technique for benign and malignant breast nodules.

breast cancer is the most common malignancy in women and the second leading cause of cancer deaths worldwide. therefore, early detection of breast cancer and timely treatment are of great significance for controlling and reducing breast cancer mortality. breast ultrasound is an adjunct to extensive use in the detection of breast cancer, but ultrasound is highly technically dependent on the examiner, and the results are greatly influenced by the subjective nature of the examiner, adding unnecessary surgery and puncture, which causes great problems for clinicians and patients.moreover, the value of conventional ultrasound in the differential diagnosis of breast mass is still limited, and the emergence of new technologies such as artificial intelligence and elastography has improved the accuracy of ultrasound diagnosis to varying degrees. s-detect technology is a computer-aided (cad) system recently developed by samsung medical center for breast ultrasound to assist in morphological analysis based on the breast imaging reporting and data system (bi-rads) description and final assessment.this provides a new way to identify the benign and malignant breast nodules. the e-breast technique, unlike conventional strain-elastic imaging technology, performs an elastic analysis of the entire two-dimensional image.moreover, when measuring the elastic ratio, it is only necessary to place a region of interest (roi) at the nodule.compared with the average elasticity of the surrounding area, it is more reflective of the elastic ratio of the mass to the surrounding tissue.

Eligibility criteria:
inclusion criteria: 1. had breast lesions detected by ultrasound 2. age 18 or older 3. upcoming fnab or surgery 4. signing informed consent exclusion criteria: 1. patients who had received a biopsy of breast lesion before the ultrasound examination 2. can not cooperate with the test operation 3. patients who were pregnant or lactating 4. patients who were undergoing neoadjuvant treatment.

Keywords: artificial intelligence; ultrasound; breast nodule; eci
biomarkers for acute graft-versus-host disease

Conditions: Acute GVH Disease

Summary: validation of already described biomarkers on acute gvhd prediction and severity fecal calprotectin and alpha 1 anti-trypsin, plasmatic rer3a, il-8, elafin, tnfar1, il-2r alpha, hgf

description of the project: the main objective of this prospective biological single center study (non interventional) is to identify non invasive biomarkers able to diagnose acute gvhd and/or predict outcome of patients with acute gvhd. the primary objective of the study is double: (1): to evaluate markers as diagnostic markers of gvhd (2): to evaluate the potential of the markers as risk factor for steroid-refractory acute gvhd occurrence. secondary objectives are: -to evaluate the markers as risk factors for gvhd -to evaluate the potential of these markers as prognostic factors of 6-month non-relapse mortality in patients with acute gvhd-to evaluate the additional value of the biomarkers to predict gvhd or steroid-refractory gvhd as compared to other known and routinely used risk factors (clinical grading system, performance status, albuminemia...). stools and blood will be on day 7, 14, 21, 28 after transplantation and the first day of digestive gvhd. management of patients will not differ from the usual care. fecal calprotectin and alpha 1 anti-trypsin, plasmatic rer3a, il-8, elafin, tnfar1, il-2r alpha, hgf will be measured at each points by elisa tests. 315 patients would be sufficient to estimate the area under the roc curve with a half-width of the 99% confidence interval of 0.05, assuming 60% of patients would develop acute gvhd, and normally distributed markers. the diagnosis and prognosis values will be analyzed separately. expected results: if some biomarkers are found significantly associated with diagnosis or prognosis of acute gvhd, they will be compared with the current clinical, biological and histological markers. indeed, these markers have a clinical potential impact only if they give similar or better information than routine currently available markers, ie: clinical gvhd grading system, performance status, gut endoscopy and histology. the non-invasivity of these biomarkers should also be taken into account (in comparison to histology). identification of diagnostic markers will avoid useless treatment with high dose corticosteroids in patients without gvhd identification of prognostic markers will comfort the decision of a second-line treatment sooner than usually, ie: at gvhd onset. indeed, the onset of a second-line treatment after a steroid-refractory gvhd varies from 3 to 21 days depending on clinical evolution of patients. if some prognostic markers are available at diagnosis, delay in second-line treatment can be shortened and the patient can consequently have an increased chance to response to an early treatment. identification of prognostic markers will also guide the corticosteroids decrease in patients with good prognosis gvhd

Eligibility criteria:
inclusion criteria: * adult patients receiving an allogeneic transplant * informed consent signed exclusion criteria: * patient refusal
daptomycin for the treatment of infections due to gram-positive bacteria

Conditions: Gram-Positive Bacterial Infections

Summary: the purpose of this study is to provide daptomycin, an antibiotic, to patients who are failing conventional therapy, or who cannot take approved antibiotics for one reason or another.


Eligibility criteria:
main inclusion criteria: * infection caused by staphylococcus aureus, staphylococcus epidermidis, enterococcus faecalis, or enterococcus faecium that requires inpatient hospitalization and treatment with injectable antibiotics\*\* * site of infection: complicated skin and skin structure infection; urinary tract infection; intra-abdominal infection; infective endocarditis; or bloodstream infection (including catheter-related). * pathogen resistant to, or patient intolerant of: beta-lactams, vancomycin, quinupristin/dalfopristin, or linezolid. * unable to receive any other standard commercially available antibacterial therapy for the infection. main exclusion criteria: * creatinine clearance less than 40 ml/min\*\* * hemodialysis or peritoneal dialysis * admitted to the hospital for drug overdose or other conditions associated with rhabdomyolysis, or is expected to require repeated intramuscular injections * creatine phosphokinase (cpk) level greater than 2.5 times above the upper limit of normal (uln) at screening; if the elevation in cpk can be attributed to an obvious cause (eg, surgery)\*\* * central nervous system infection * pulmonary infection. (\*\*) an exemption may be granted for patients not satisfying these criteria following a conversation with the medical monitor.

Keywords: gram positive bacterial infections expanded access program resistant infections bacteremia bacterial and fungal infections bacterial infections
pit: prophylactic irradiation of tracts in patients with malignant pleural mesothelioma

Conditions: Mesothelioma

Summary: the pit (prophylactic irradiation of tracts) trial will determine whether or not pit radiotherapy is effective in preventing or delaying the onset of chest nodules in patients with mesothelioma.

mesothelioma is a rare form of cancer affecting the protective lining that covers many of the body's internal organs. the most commonly affected areas are the lungs and internal chest wall. in the uk over 2300 patients are diagnosed with mesothelioma each year and the numbers are increasing. as part of the diagnosis and treatment of mesothelioma, patients may undergo a procedure which involves inserting a thin tube into the chest wall enabling an internal examination and for any biopsies or samples of fluid to be taken. these procedures can result in the development of skin lumps or nodules along the tract created by inserting the tube. to try and reduce the risk of these nodules developing in the tract or at the site of the scar, radiotherapy can be given to the chest wall at the site of the tract after the procedure has been performed; this type of radiotherapy is known as prophylactic irradiation of tracts or pit. although many hospitals already give patients this type of radiotherapy treatment to the chest wall we still do not know if the treatment works. this trial has been designed to answer the question about the effectiveness of pit radiotherapy. if pit is found to be effective in preventing or delaying the development of these skin nodules then it can be offered to all patients as part of their treatment. however, if we discover that pit is not effective this will save patients from undergoing ineffective treatment and having to spend time making unnecessary extra visits to hospital

Eligibility criteria:
inclusion criteria: * either sex, age ≥ 18 years * diagnosis of mesothelioma by multi-disciplinary team (mdt). all histological subtypes are eligible for the trial * ecog performance status 0-2 (appendix c) * inoperable disease or operable disease in patients unsuitable for surgery as decided by a mdt * chest wall intervention with video-assisted thoracoscopy (vats), open surgical biopsy (mini-thoracotomy), local anaesthetic thoracoscopy or chest drain * able to start radiotherapy within 42 days (6 weeks) of the most recent chest wall procedure * chest wall intervention scar visible at time of randomisation * radiotherapy target volume acceptable by the local radiotherapist * patients enrolled on other clinical trials could be considered after discussion with the chief investigators exclusion criteria: * patients who underwent a thoracotomy (as large thoracotomy scars may not be adequately covered by this radiotherapy technique) * previous radiotherapy to the region of the chest wall intervention site * indwelling pleural catheter in-situ at the intervention site * patients currently receiving chemotherapy

Keywords: mesothelioma radiotherapy prophylactic irradiation of tracts
unilateral wrist extension training after stroke

Conditions: Stroke

Summary: following stroke, muscle weakness and impaired motor function are expressed in both the more (ma; paretic) and less affected (la; non-paretic) sides. although the efficacy of resistance training is well recognized, training the ma limb directly may be initially difficult due to muscular weakness. "cross-education" is training one side of the body increases strength in the untrained and opposite side. this concept can be applied in strength training when training the more affected sides cannot be initiated. recently, our lab found six weeks of dorsiflexion resistance training in the la leg improved the strength of both trained and untrained legs of chronic stroke participants. the current project explored if cross-education exists in the upper limb in chronic stroke participants and if there are related changes in cortical and spinal cord plasticity. we hypothesized that unilateral strength in the less affected arm could enhance wrist extension strength bilaterally with related neural adoption and improved clinical function.

stroke produces muscle weakness seen on both more (paretic, ma) and less affected (non-paretic, la) sides. "cross-education" is training one side of the body increases strength or motor skill in the same muscles on the untrained side. this can be applied to enhance muscle strength in the ma side and we found that 6 weeks of dorsiflexion resistance training with the la leg improved strength bilaterally in chronic stroke. to explore if cross-education occurs also in the upper limb after stroke, participants will complete a 5-week unilateral wrist extension training. twenty four participants will be recruited, 12 from rehabilitation neuroscience laboratory at university of victoria, 12 from brain behaviour laboratory at university of british columbia. before and after training, maximal voluntary contraction wrist extension force was measured with a 6-axis load cell using cartesian coordinates (fz = extension). electromyography of extensor and flexor carpi radialis, biceps and triceps brachii were recorded. fugl-meyer and partial wolf motor function test were performed by the same physical therapist at each location. reciprocal inhibition from wrist flexors to extensors, cutaneous reflexes evoked by median and superficial radial nerve stimulation were assessed in those at uvic. cortical silent period, short-interval intracortical inhibition, intracortical facilitation and transcallosal inhibition from transcranial magnetic stimulation were measured in participants at ubc.

Eligibility criteria:
inclusion criteria: * over 6 months post-stroke; * one side of arm shows muscle weakness * pass the screening test of physical activity readiness questionnaire * pass the screening test for dementia * free from dementia (score \< 24 on the montreal cognitive assessment) and any other contradiction for tms test exclusion criteria: * had medication affecting muscle tone within the past 3 months * wear a pacemaker

Keywords: stroke strength training rehabilitation
to evaluate the safety and efficacy of gc1111 (recombinant human iduronate-2-sulfatase) in hunter syndrome patients

Conditions: Mucopolysaccharidosis II

Summary: the purpose of this study is to evaluate the safety and efficacy of gc1111 (recombinant human iduronate-w-sulfatase) in hunter syndrome (mucopolysaccharidosis ii) patients


Eligibility criteria:
inclusion criteria: 1. patients with diagnosis of mps ii based on both clinical and biochemical criteria 2. male, ages 6 to 35 years old 3. patients who are able to comply with the study requirements 4. patients who have given voluntary written consent to participate in the study 5. patients who is acceptable for using an appropriate method of contraception exclusion criteria: 1. history of a tracheostomy or a bone marrow transplant 2. known hypersensitivity to idursulfase 3. known shock to idursulfase 4. history of receiving treatment with another investigational therapy within the past 30 days 5. history of a stem cell transplant 6. known hypersensitivity to any of the components of idursulfase 7. female

Keywords: hunter syndrome mps ii idursulfase
clinical study of g protein biased μ - opioid receptor agonist oliceridine for optimizing postoperative analgesia under general anesthesia

Conditions: Old Age

Summary: traditional opioid analgesia is a treatment method for moderate to severe pain. however, the use of opioid drugs is not without risks. when treating acute pain, patients may experience hypotension, respiratory depression, hypoxia, nausea and vomiting, irritability, and itching. the purpose of this study is to evaluate the comparison of g protein biased μ - opioid receptor agonist oliceridine and traditional μ - opioid receptor agonist sufentanil in terms of analgesia in patients under general anesthesia.

all patients who met the inclusion criteria were randomly divided into two groups based on the use of postoperative analgesic pumps: the sufentanil group and the oliceridine group. the sufentanil group received a treatment regimen of sufentanil 2 µ g · kg-1; the treatment regimen for the oliceridine group is oliceridine 0.4mg · kg-1. the main postoperative observation indicator is the measurement of total pain intensity difference within 48 hours (spid-48).

Eligibility criteria:
inclusion criteria: 1. age\>65 years old 2. asa level i-iii 3. bmi 18.5-29.9 4. patients undergoing knee joint surface replacement surgery under general anesthesia 5. postoperative patient controlled intravenous analgesia pump (pcia) treatment 6. possess reading and writing abilities 7. you can sign an informed consent form exclusion criteria: 1. suffering from chronic pain or mental illness before surgery 2. unable to communicate due to cognitive impairment or language barriers before surgery 3. patients who have used opioid drugs three days before surgery 4. patients with long-term alcohol consumption 5. abnormal liver and kidney function or dialysis patients 6. concurrent severe cardiovascular, respiratory, and autonomic neuropathy 7. participated in clinical studies of other drugs or medical devices in the past 3 months

Keywords: old age knee arthroplasty pain
evaluation of the incidence of cancer in the follow-up of women with 3 consecutive embryonic demises before 10 weeks or 1 fetal death, according to their thrombophilia status, with a special focus on women with an obstetric antiphospholipid symdrome (oaps)

Conditions: Antiphospholipid Syndrome; Pregnancy Related; Cancer

Summary: a number of case reports describe the association of antiphospholipid antibodies (apl abs) with hematological and solid organ malignancies. especially in elderly patients, thrombotic events associated with apl abs can be the first manifestation of malignancy. cancer-associated monoclonal gammopathy of the igm type can be accompanied by positive lupus anticoagulant (la) or an anticardiolipin (acl) igm. cancer and antiphospholipid antibody syndrome (aps) can coexist in sporadic cases, while some cancer patients with or without thrombosis may show some transitory apl ab positivity, the most striking symptomatic clinical feature, catastrophic aps, being even described in cancer patients. some reports suggest a significant incidence of malignancies in aps patients. cancer was the 2nd cause of death (13.9%), after bacterial infection, during the 10-year follow-up of the 1,000 aps patients studied by the euro-phospholipid project group, but no control group was simultaneously evaluated. the risk of cancer in patients with aps is thus still uncertain. the nîmes obstetricians and haematologists aps (noh-aps) study was based on the recruitment of a cohort of women with no history of thrombosis, who had experienced pregnancy loss fulfilling the clinical criteria of obstetrical aps (oaps), who were either positive for apl abs (aps group), or positive for the f5 rs6025 or f2 rs1799963 polymorphism (thrombophilia group), or negative for thrombophilia screening (control group). we now want to assess the comparative incidence of cancer in women for whom an oaps diagnosis had been made. this evaluation will be carried out during the 2017 medical follow-up step, corresponding to a median follow-up of 17 years. an external, local population-derived control group, the registry of tumors in montpellier area (registre des tumeurs de l'hérault) will be used to compute standardized incidence ratios (sirs).


Eligibility criteria:
inclusion criteria: women initially included into the noh-aps cohort (n=1,592): no history of thrombosis, pregnancy loss fulfilling the clinical criteria of obstetrical aps, i.e. 3 unexplained consecutive embryonic demises before 10 weeks or 1 unexplained fetal death exclusion criteria: women included into the noh-aps cohort, lost to follow-up (n=37).
metabolomics-based detection of colorectal cancer

Conditions: Colorectal Cancer

Summary: the purpose of this study is to collect specimens to perform metabolic profiling of serum and urine from patients with colorectal cancer, colon polyps and healthy patients.

in this study, metabolite profiling analysis will be carried out on colon cancer patients at the time of diagnosis and during the course of treatment, using patient tissue and serum samples. samples of serum (1 ml) and tissue specimens (50 mg each) from colorectal cancer patients (stages i-iv) and serum samples from an equal number of age and gender-matched healthy controls will be obtained under identical (8-hour overnight fasting) conditions. metabolic profiles will be identified using the nmr and ms instruments located in purdue's on-campus nmr and ms facilities. multivariate statistical analyses will be used to monitor changing metabolite profiles that indicate changes in disease status. we anticipate that putative biomarkers will be easier to identify in the cancerous tissue, and the concentrations of these metabolites will then be quantified in the patients' serum, that ultimately would allow for easier detection of colon cancer.

Eligibility criteria:
inclusion criteria: * patients with resectable colorectal cancer must have samples collected (serum/urine) prior to surgery and/or after surgery, but prior to starting chemotherapy. * patients with metastatic colorectal cancer must have samples collected prior to initiating chemotherapy, and after chemotherapy initiation: every 3 months for up to 24 months. * subjects must be ≥ 18 years of age. * subjects undergoing screening colonoscopy are able to participate as healthy controls or as patients with colon polyps if colonoscopy identifies colon polyps being present (informed consent will be signed first and samples will be collected; after colonoscopy the samples will be identified as "healthy" or "polyps"). * for patients who underwent biopsy or surgery for colorectal cancer, enough tissue needs to be available for testing, as appropriate per patients groups in the protocol schema. * subjects must be able to attend follow up or treatment visits per investigator's recommendations for up to 24 months for collection of serum/urine specimens. * female patients known to be pregnant are not eligible for this protocol. * subjects must be able to undergo an 8-hr overnight fast prior to metabolomic testing exclusion criteria: * presence of an invasive cancer other than colorectal cancer is an exclusion criterion

Keywords: colorectal cancer metabolomics
five plus year efficacy of endoscopic sleeve gastroplasty (esg) for sustained weight loss

Conditions: Obesity and Obesity-related Medical Conditions; Weight Loss

Summary: the objective of this study is to assess the long term weight loss and weight loss journey of patients who received an endoscopic sleeve gastroplasty (esg) 5 or more years prior to enrollment.

includes retrospective data collection and one prospective visit

Eligibility criteria:
inclusion criteria: * subject is ≥ 18 years of age at the time of the esg procedure * subject with a bmi between 30 kg/m2 and 50 kg/m2, inclusive, at the time of the primary esg procedure using overstitch endoscopic suturing system * subject completed follow-up 1-year from the esg procedure for weight loss management * subject completed or is eligible for follow-up 5-years from the esg procedure for weight loss management (visit can be collected either retrospectively or prospectively) * subject has returned for a minimum of one annual follow-up at the treating site for weight loss management annually between two and four years from the procedure. * subject is willing to complete one prospective visit (5 year or 5+ year, as appropriate) * subject is able to read, understand, and sign a written informed consent form to participate in the study exclusion criteria: * none